| Trial ID | NCT05961501 |
| Status | Enrolling By Invitation |
| Condition | Myalgia |
| Intervention | An aqueous solution containing CBD and CBN |
Facial pain and headaches of muscular origin affect millions but lack standardized treatment protocols. This trial addresses a critical gap by evaluating specific cannabinoid combinations using objective electromyographic measurements rather than subjective pain scales alone.
This randomized, double-blind, placebo-controlled trial enrolls 42 adults with chronic (>3 months) facial pain and headache of muscular origin. Participants receive either an aqueous CBD/CBN solution or placebo for 60 days, with outcomes measured via electromyography, pressure pain threshold testing, and clinical examination at baseline, day 20, 40, and 60. The trial is currently enrolling by invitation and represents one of the first controlled studies examining this specific cannabinoid combination for myofascial pain.
“If positive, this trial could provide the evidence base I need to confidently recommend specific CBD/CBN formulations for patients with chronic facial myalgia. The objective EMG endpoints are particularly valuable for establishing clinical credibility.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This trial item was assembled from normalized source metadata and pipeline scoring.
